Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 14, 2008

Alexion Purchases Patents Related to Approved Drug from OMRF for $10M

  • Alexion Pharmaceuticals will pay $10 million to acquire rights to certain Oklahoma Medical Research Foundation (OMRF) patents including those covering the company’s drug paroxysmal nocturnal hemoglobinuria (PNH), Soliris. The agreement thus obviates the legal dispute between Alexion and OMRF.

    Alexion will make the payment in various amounts to be remitted in 2008 and the first half of 2009. No further amounts including royalties will be owed to OMRF related to sales of Soliris or other uses of the OMRF patents. Also, the claims filed by OMRF and counterclaims filed by Alexion in the U.S. District Court for the Northern District of Oklahoma will be dismissed.

    The deal covers certain inventions related to complement-inhibition technology made in the 1980s relating to the treatment of complement system mediated disorders. Alexion has had limited rights as a licensee since 1992. The firm is engaged in developing mAbs to block the body's complement system. Soliris stemmed from this research and was approved in 2007.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »